Home›Search›Journal for ImmunoTherapy of Cancer

Journal for ImmunoTherapy of Cancer

BMJ Publishing Group · United Kingdom · Est. 1973

ISSN2051-1426eISSN2051-1426
SJR Q1✓ WOS SCIE✓ Scopus / SJR✓ DOAJ✓ Open Access
100
/ 100
High Trust
PubScope credibility score from verifiable indexing & ethics signals
Score Breakdown
◆ WoS flagship (SCIE/SSCI/AHCI)78
✓ Corroboration (4 more)+22
Total100
Level data: Norwegian Register (HK-dir), NLOD 2.0. · Third-party records · how this is calculated · Report an error →
⚡ Speed vs Prestige
How does this journal balance review speed with impact level?
18
weeks to publish · journal-reported
Average · vs ~15 wk median
Q1
SJR Rank
Top 25% in field
Impact Factor & Quartile · Web of Science (JCR)

✓ Indexed in the Web of Science Core Collection (SCIE) — Clarivate publishes an official Journal Impact Factor and JCR quartile for this journal.

See the official Impact Factor & quartile on the journal’s page ↗

The Impact Factor & JCR quartile are licensed by Clarivate — we link you to the official source instead of reprinting a number that can go out of date. Open metrics below: SCImago Q1 · Scopus CiteScore 17.8. Source: Clarivate Journal Citation Reports.

SJR Scorei
4.114
H-Indexi
179
CiteScorei
17.8
SNIPi
1.745
Total Worksi
5,645
Total Citationsi
198,805
2yr Mean Citednessi
7.34
Open Impact Factor alternative
Retractions
1
Source: Retraction Watch

Aims & Scope

The Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer-reviewed journal that aims to enrich communication and advance scientific understanding in the rapidly evolving fields of tumor immunology and cancer immunotherapy. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.

General Information

Country / RegionUnited Kingdom
Primary LanguageEnglish
1st Year Published1973
Annual Volume~ 553 articles / year
StatusActive (last: 2026)
Total Publications5,645
Publisher OrgBMJ
OA Since2012
Visit Journal Website

Submission Info

Peer ReviewSingle-blind
Review Time~18 weeks
Acceptance Rate21%
OA LicenseCC BY, CC BY-NC, CC BY-NC-ND
OA Rate—

Ethics & Quality

COPE Member✗ No
OASPA Member✗ No
Not on Predatory Lists✓ Yes
Plagiarism Detection✓ Yes
📦 Long-term Preservation
LOCKSSPMC

Think.Check.Submit Compliance

10/12 · 83%
✅
Do you know the journal / publisher?
BMJ Publishing Group
✅
Does the journal have a website?
✓ Linked
✅
Is the ISSN verified?
2051-1426 / 2051-1426
✅
Indexed in a trusted database?
WoS, Scopus, DOAJ, PubMed
✅
Peer review process documented?
Single-blind
❌
Follows ethical publishing standards (COPE)?
N/A
❌
APC fees clearly disclosed?
N/A
✅
Not on predatory/blacklists?
✓ Clean
✅
Long-term digital preservation?
LOCKSS, PMC
✅
Plagiarism detection in place?
Yes
✅
Listed in DOAJ (verified OA)?
DOAJ verified
✅
Primary language documented?
English

Based on the Think.Check.Submit framework by DOAJ, COPE & OASPA. All data from verified open sources.

Publication & Citation Trend

Articles published
Citations received
365
35k
2019
564
37k
2020
644
33k
2021
567
25k
2022
476
13k
2023
479
8.2k
2024
704
4.4k
2025
314
151
2026

Source: OpenAlex · Each year’s green bar = citations earned by that year’s papers, counted to date — so recent years look lower simply because their papers haven’t had time to be cited yet.

SJR Quartile by Discipline

Scimago ranks this journal separately in each subject category — its quartile can differ by discipline.

Cancer ResearchQ1
ImmunologyQ1
Immunology and AllergyQ1
Molecular MedicineQ1
OncologyQ1
PharmacologyQ1

Subject Classification

Web of Science Categories

ImmunologyOncology

Scopus Categories

Molecular MedicinePharmacologyImmunologyCancer ResearchImmunology and AllergyOncology

Research Topics (OpenAlex)

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy researchImmune Cell Function and InteractionImmune cells in cancerMonoclonal and Polyclonal Antibodies ResearchVirus-based gene therapy researchFerroptosis and cancer prognosisCancer Research and TreatmentsT-cell and B-cell Immunology

Frequently asked questions about Journal for ImmunoTherapy of Cancer

Is Journal for ImmunoTherapy of Cancer a predatory journal?

PubScope has no integrity flags on record for Journal for ImmunoTherapy of Cancer: it is indexed in Web of Science, Scopus, DOAJ, and is not on DOAJ's withdrawn list. Its PubScope Trust Score is 100/100. Indexing is a transparency signal, not a guarantee — always confirm fit and policies before submitting.

What is the impact factor of Journal for ImmunoTherapy of Cancer?

Journal for ImmunoTherapy of Cancer is indexed in the Web of Science Core Collection, so Clarivate publishes an official Journal Impact Factor for it (since the 2023 Journal Citation Reports, every Core Collection journal — including Arts & Humanities and Emerging Sources titles — receives one). PubScope links to Clarivate's official source rather than reprinting the number, which can be out of date. As an open alternative, its Scopus CiteScore is 17.8.

Is Journal for ImmunoTherapy of Cancer indexed in Scopus and Web of Science?

Journal for ImmunoTherapy of Cancer is indexed in Web of Science, Scopus, DOAJ.

What is the aims and scope of Journal for ImmunoTherapy of Cancer?

The Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer-reviewed journal that aims to enrich communication and advance scientific understanding in the rapidly evolving fields of tumor immunology and cancer immunotherapy. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.

What is the acceptance rate of Journal for ImmunoTherapy of Cancer?

Journal for ImmunoTherapy of Cancer lists a self-reported acceptance rate of approximately 21%. Journal-reported figures can be optimistic — treat it as a rough guide, not a guarantee.

You May Also Like

See all →
OncoImmunology
Taylor & Francis Group
SJR Q1SCIEOA
OncoImmunology
Landes Bioscience
SJR Q1
Cancer Immunology, Immunotherapy
Springer Science and Business Media Deutschland GmbH
SJR Q1SCIEOA
Cancer Immunology Research
American Association for Cancer Research Inc.
SJR Q1SCIE
Compare This JournalFind Similar← Back to Search
Understand these signals
How to tell if a journal is predatoryWhat Q1–Q4 quartiles meanWeb of Science vs Scopus vs DOAJWhat is an APC?

Data updated: 2026-05-22 · Sources: SJR, DOAJ, OpenAlex, WoS, Crossref